Hayfin Capital Management is an independent investment firm that offers lending solutions to European middle-market companies.
Business Model:
Revenue: $5M
Employees: 51-200
Address: One Eagle Place
City: London
State: england
Zip: SW1Y 6AF
Country: GB
Hayfin was founded in 2009 with the ambition of creating one of Europe’s leading investment platforms. They focus on delivering best-in-class risk-adjusted returns for their investors across four strategies: Direct Lending, Special Opportunities, High-Yield Credit and Securitized Credit. Hayfin is a London based firm with offices in Amsterdam, Frankfurt, Mardid, Paris and Luxembourg. They consider their selves value investors, generating differentiated return through hard work, insightful analysis and disciplined investing. Hayfin seeks to recruit and retain exceptionally talented professionals. They believe in being local in each of their markets, and that their diverse mix of nationalities, cultures and languages makes them more connected to these markets. Most of their team are industry generalists, with their edge lying in their origination networks and proven expertise in managing complex restructurings, workouts and liquidations. That said, they employ dedicated, specialist teams in the areas of healthcare (life sciences), shipping (maritime) and real estate, where they believe their focused expertise provides an advantage. They operate across all major European geographies with offices in London, Paris, Madrid, Frankfurt, Luxembourg and Tel Aviv, and have a growing presence in the United States with an office in New York.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2023 | HeartFlow | Series F | 0 |
1/2015 | NKD | Debt Financing | 0 |
7/2020 | MiMedx Group | Post-IPO Debt | - |
6/2022 | KEO World | Venture Round | 0 |
3/2022 | ADMA Biologics | Post-IPO Debt | 0 |
2/2022 | KEO World | Debt Financing | 0 |
7/2020 | Amicus Therapeutics | Post-IPO Debt | 0 |
10/2018 | GC Aesthetics | Equity | 97M |
10/2018 | Avadim Health | Debt Financing | 0 |
6/2022 | KEO World | Venture Round | 0 |
3/2022 | ADMA Biologics | Post-IPO Debt | 0 |
2/2022 | KEO World | Debt Financing | 0 |
7/2020 | Amicus Therapeutics | Post-IPO Debt | 0 |
7/2020 | MiMedx Group | Post-IPO Debt | - |
10/2018 | GC Aesthetics | Venture Round | 0 |
10/2018 | Avadim Health | Debt Financing | 0 |
1/2015 | NKD | Debt Financing | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|